High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR by unknown
Wang et al. Journal of Translational Medicine 2013, 11:90
http://www.translational-medicine.com/content/11/1/90RESEARCH Open AccessHigh EGFR copy number predicts benefits from
tyrosine kinase inhibitor treatment for non-small
cell lung cancer patients with wild-type EGFR
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Background: This study was designed to determine whether advanced non-small-cell lung cancer (NSCLC) patients
with high copy number of epidermal growth factor receptor (EGFR) can benefit from treatment with EGFR-tyrosine
kinase inhibitors (TKIs).
Methods: EGFR gene copy number was assessed by fluorescence in situ hybridization (FISH) and EGFR mutations
was tested using Luminex xTAG technology in 502 TKI-treated NSCLC patients. The association between both
biomarkers and clinical benefit from EGFR-TKI were analyzed.
Results: EGFR FISH + and EGFR mutations were significantly associated with higher response rates (37.2% and
43.7%, respectively), superior progression-free survival (PFS) (FISH+, 11.2 months; hazard ratio [HR], 0.51; 95% CI,
0.42 to 0.62; p < 0.001; mutation+, 11.7 months; HR, 0.37; 95% CI, 0.31 to 0.45; p < 0.001) and overall survival (OS)
(FISH+, 30.2 months; HR, 0.51; 95% CI, 0.40 to 0.65; p < 0.001; mutation+, 30.2 months; HR, 0.45; 95% CI, 0.36 to 0.58;
p < 0.001). In patients with wild-type EGFR, EGFR FISH + correlated with longer PFS than EGFR FISH- status
(4.4 months vs. 2.0 months; HR, 0.56; 95% CI, 0.41 to 0.75; p < 0.001), so did amplification (5.0 months vs. 2.0 months;
HR, 0.43; 95% CI, 0.24 to 0.76; p = 0.003). However, FISH + had no association with improved PFS in EGFR-mutated
patients (HR, 0.77; 95% CI, 0.57 to 1.03; p = 0.076).
Conclusions: A combined analysis of EGFR FISH and mutation is an effective predictor of EGFR-TKI therapy. Specifically,
a high EGFR copy number may predict benefit from TKIs treatment for NSCLC patients with wild-type EGFR.
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Increasing evidence indicates that activation of somatic
mutations in the EGFR kinase domain (exons 18–21) [1,2]
confers sensitivity to the EGFR TKIs, such as gefitinib and
erlotinib for patients with advanced NSCLC. Several phase
3 randomized trials have shown that EGFR-TKIs offered
significant benefits over standard chemotherapy in pa-
tients with EGFR mutation-positive tumors [3-7]. As an
independent molecular subtype, the detection of EGFR* Correspondence: shaojy@sysucc.org.cn; wmzhang79@126.com
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reproduction in any medium, provided the ormutations have been recommended in the National
Comprehensive Cancer Network (NCCN) clinical prac-
tice guidelines in oncology (version 3.2011) to predict TKI
sensitivity in clinical practice.
An increase in EGFR copy number may serve as a con-
tributory mechanism for the activation of EGFR tyrosine
kinase, and may trigger downstream oncogenic pathways
[8,9]. A high EGFR copy number showed a trend toward
poor prognosis in the absence of EGFR-TKI treatment
[10,11]. Recent studies have shown that high EGFR gene
copy number is associated with increased response rates
to TKI therapy, as well as improved PFS [12,13] and
OS[14-16]. Several studies have demonstrated that
increased EGFR gene copy number and mutations display
a high degree of overlap and the fluorescence in-situtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutations was approximately 62.5% to 77.6% [3,17-20].
Although EGFR mutations can account for most of
the objective responses to EGFR-TKIs therapy, the
clinical benefits cannot only be explained by these muta-
tions. Considering with mutant allele specific imbalance
of oncogenes in tumor cells harboring gene mutation,
copy number gain of EGFR usually occurred in the cells
with an EGFR mutation [21]. It appears that the associ-
ation between EGFR FISH + tumors and TKI sensitivity
is due to coexisting EGFR mutations. In contrast to
consistent reports of EGFR mutations correlating with
improved response rates, reports regarding the predict-
ive value of EGFR gene copy number have been incon-
sistent. Therefore, we sought to determine whether
high EGFR copy number could be an alternative pre-
dictor for the efficacy of EGFR-TKIs in EGFR wild-type
tumors.
In this study, we retrospectively detected EGFR muta-
tions and gene copy number in order to evaluate the
predictive value, alone or combined, for TKI efficacy and
survival in TKI-treated patients.
Methods
Patient selection
This retrospective study included patients with histologi-
cally confirmed stage IIIb, stage IV, or recurrent NSCLC
who received gefitinib or erlotinib treatment at any time
during the course of their disease, between April 2004 and
March 2011 at three Chinese institutions: Sun Yat-sen
University Cancer Center, the First Affiliated Hospital of
Sun Yat-sen University, and the Military General Hospital
of Guangzhou. Patients were selected based on the follow-
ing criteria: sufficient tumor tissue from primary or meta-
static tumors obtained at the time of initial diagnosis for
detection of EGFR mutations and FISH status, the pres-
ence of at least one measurable lesion according to the
Response Evaluation Criteria In Solid Tumors (RECIST
version 1.0) [22], and complete follow-up information (at
least one evaluation before disease progression, more than
three months after follow-up, or upon death). Patients
were excluded if they had uncontrolled brain metastases
or other primary cancers that were diagnosed either
before or after NSCLC. Clinical follow-up information
was obtained from the medical records of in-patients or
out-patients, as well as telephone interviews. The study
was approved by the Research Ethics Committee of the
Sun Yat-sen University Cancer Center.
The medical history of each patient was documented
by a retrospective chart review, which included age at diag-
nosis, gender, dates of diagnosis and death, postoperative
disease recurrence, Eastern Cooperative Oncology Group
(ECOG) performance status at the start of treatment with
an EGFR-TKI, the number of previous chemotherapyregimens received, prior administration of a platinum-
based drug, the EGFR-TKI administered (gefitinib or
erlotinib), and subsequent treatment after progression.
Tumor histology was classified according to the World
Health Organization (WHO) criteria [23]. Clinical stage
was based on the revised international staging system for
lung cancer by the Union for International Cancer Control
(UICC) [24] in 2009. Smoking status was categorized as
ever or never (<100 lifetime cigarettes).
Gefitinib or erlotinib were administered orally (250 mg
or 150 mg, respectively) once daily until disease progres-
sion, intolerable toxicity, or patient refusal. Clinical
response was assessed every 3–10 weeks by radiologic
examination (computed tomography or magnetic reson-
ance imaging). Brain magnetic resonance imaging or
radionuclide bone scans were added when brain or bone
metastasis was suspected. The response was evaluated
according to the RECIST criteria.
DNA extraction and EGFR mutation detection
The QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany) was used to extract DNA from paraffin-
embedded tissues, and the operational tumor samples
with histological control for the presence of tumor cells
(> 70%) that was obtained by trimming the normal tissue
and necrotic tissue.
EGFR mutations were analyzed by using The SurplexW
EGFR Mutation Kit (Surexam Bio-Tech, Guangzhou, China)
to screen for 22 mutations (Additional file 1: Table S1)
of EGFR exons18–21 in an x-TAG liquidchip assay. The
main procedures are listed as follows [25]: EGFR gene frag-
ments were obtained by PCR containing 22 mutation sites;
and the excess primers and dNTPs were removed by exo-
nuclease I and alkaline phosphatase (EXO-SAP). The EXO-
SAP-cleaned PCR product was subjected to an allele specific
primer extension (ASPE) step where a universal tag was
linked to a specific primer sequence complementary to
EGFR. The ASPE products were hybridized to specific anti-
tag probes that were pre-coated on the magnetic micro-
spheres. The magnetic microspheres were then applied to
the Luminex 200 (Luminex Corp., Austin, TX) and median
fluorescence intensity was read.
EGFR FISH assay
Gene copy number per cell was investigated by FISH
using the LSI EGFR Spectrum Orange/CEP7 Spectrum
Green probe (Vysis, Abbott Laboratories, Illinois, USA)
according to a published protocol with minor modifica-
tions. Detailed FISH staining procedures are described
in our previously published articles [26]. FISH signals for
each locus-specific FISH probe were assessed under an
Olympus BX51 TRF microscope (Olympus, Japan)
equipped with a triple-pass filter (DAPI/Green/Orange,
Vysis). FISH analysis was independently performed by
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ristics and molecular variables of the patients. A scheme
for classifying NSCLC tumors as EGFR FISH + and EGFR
FISH- was developed at the University of Colorado, and
has been used in multiple clinical studies. FISH results for
NSCLC were determined according to a previous descrip-
tion [14,27,28]. Patients were classified into six FISH strata
with an increasing number of EGFR gene copies per cell
according to the frequency of tumor cells with a specific
number of EGFR gene copies and chromosome 7 centro-
mere: disomy (≤ 2 copies in > 90% of cells); low trisomy (≤
2 copies in ≥ 40% of cells, 3 copies in 10%–40% of the cells,
≥ 4 copies in <10% of cells); high trisomy (≤ 2 copies in ≥
40% of cells, 3 copies in ≥ 40% of cells, ≥ 4 copies in < 10%
of cells); low polysomy (≥ 4 copies in 10% – 40% of cells);
high polysomy (≥ 4 copies in ≥ 40% of cells); and gene
amplification (defined by presence of tight EGFR gene
clusters and a ratio of EGFR gene to chromosome of ≥ 2
or ≥ 15 copies of EGFR per cell in ≥ 10% of analyzed cells).
Statistical analysis
PFS as a primary endpoint was calculated from the time
of the first TKI treatment to the time of disease progression
according to RECIST criteria [22], or unacceptable toxic ef-
fects. Secondary endpoints included the objective response
rate (ORR), disease control rate (DCR) and OS. OS was
calculated from the time of first TKI treatment to patient
death from any cause or last contact. Differences in distri-
bution of baseline characteristics between groups, ORR,
and DCR, were evaluated by χ2 test. PFS, OS, and 95% con-
fidence intervals (CIs) were calculated by Kaplan–Meier
survival analysis. PFS and OS were compared between
groups using the log-rank test. Cox proportional hazards
models were used to evaluate independent predictive
factors of each biological and clinical feature associated
with survival. All statistical analyses were performed using
SPSS 16.0 for Windows (SPSS Inc., Chicago, Illinois), and
p < 0.05 was considered statistically significant.
Results
Patient characteristics
NSCLC tumors from 502 patients were detected for
EGFR FISH and EGFR mutation status among the 889 pa-
tients who were treated with EGFR-TKI. Baseline and treat-
ment characteristics are summarized in Additional file 2:
Table S2. Among the patients, 139 (27.7%) achieved an
objective tumor response, 199 (39.6%) had stable disease,
and 164 (32.7%) had progressive disease. Sixty-three
patients (12.5%) continued receiving TKIs (median dur-
ation, 4.75 months; range, 0.7 to 34.5 months) after
assessed with disease progression, and 42 patients (8.3%)
received the other TKI as subsequent treatment. The last
follow-up date was April 26, 2012 and median follow-up
was 14.9 months (range, 1 to 81.3 months). At the time ofanalysis, 73 patients (14.5%) were still receiving TKIs. In
total, 280 (55.8%) deaths occurred.
EGFR FISH and TKI efficacy
The distribution of EGFR-FISH categories was as
follows: disomy was present in 166 patients (33.1%), low
trisomy in 29 (5.8%), high trisomy in 9 (1.8%), low
polysomy in 72 (14.3%), high polysomy in 135 (27.5%),
and gene amplification in 91 (18.1%) (Figure 1A-D). Two
hundred and twenty-six patients (45.0%) were categorized
as EGFR FISH + (high EGFR copy number), and 276 pa-
tients (55.0%) were characterized as EGFR FISH- (low
EGFR copy number). FISH + patients were more likely
to be female (p = 0.007) and non-smokers (p = 0.030) (Add-
itional file 3: Table S3). There were significant differences in
ORR (p < 0.001), DCR (p < 0.001), PFS (11.2 moths vs. 3.0 -
months; HR, 0.51; 95% CI, 0.42 to 0.62; p < 0.001), and OS
(30.2 moths vs.17.2 months; HR, 0.51; 95% CI, 0.40 to 0.65;
p < 0.001) between EGFR FISH+ and EGFR FISH- patients
(Tables 1, 2).
EGFR mutation and TKI efficacy
Two hundred and fifty-seven mutations of EGFR gene
were detected in 252 (50.5%) of the 499 analyzed
patients. All the mutations detected in this study were
shown in Additional file 1: Table S1. 140 patients had a
deletion in exon 19,104 patients had an exon 21 missense
mutation, three had an exon 18 missense mutation and
five had combined mutations. Patients with EGFR muta-
tions had higher ORRs (p < 0.001), DCRs (p < 0.001), and
improved PFS (11.7 months; HR, 0.37; 95% CI, 0.31 to
0.45; p < 0.001) and OS (30.2 months; HR, 0.45; 95%
CI, 0.36 to 0.58; p < 0.001) compared to patients with
wild-type EGFR (Tables 1, 2).
In multivariate analysis, EGFR mutations (HR, 0.42;
95% CI, 0.34 to 0.53; p < 0.001) and a high EGFR copy
number (HR, 0.61; 95% CI, 0.49 to 0.76; p < 0.001) were
independent predictors of a longer PFS, in addition to
an ECOG performance status of 2 and 3 (HR, 2.53; 95%
CI, 1.97 to 3.24; p < 0.001) (Table 2).
Efficacy of TKI in patients with EGFR FISH and EGFR
mutations
A total of 499 NSCLC cases were available for combined
analysis of EGFR gene copy number and EGFR mutations
in this study. Among the 252 patients with EGFR muta-
tions, 163 (64.7%) were FISH+; there was no significant
association between FISH + and FISH- groups in terms of
age, sex, smoking status, and histology (Table 3). There
was also no significant improvement in ORR and DCR
in mutation+/FISH + patients (p = 0.821 and 0.339,
respectively) (Table 1). Moreover, median PFS (12.9 months;
95% CI, 10.0 to 15.9; p = 0.075) and OS (35.9 months; 95%
CI, 27.4 to 44.3; p = 0.055) were longer in the mutation
Table 1 Survival analysis and clinical response to EGFR-TKI treatment in relation to biomarkers of EGFR FISH and
mutation in all patients
EGFR Status PFS, months p# OS, months p# Tumor Response p*








FISH + (n = 226) 11.2 8.9-13.5 < 0.001 30.2 23.8-36.5 < 0.001 84 (37.2) 142 (62.8) < 0.001 192 (85.0) 34 (15.0) < 0.001
FISH- (n = 276) 3.0 2.1-3.8 17.2 14.6-19.7 55 (19.9) 221 (80.1) 146 (52.9) 130 (47.1)
EGFR Mutation +
(n = 252)
11.7 10.0-13.3 < 0.001 30.2 24.8-35.6 < 0.001 110 (43.7) 142 (56.3) < 0.001 227 (90.1) 25 (9.9) < 0.001
EGFR Mutation –
(n = 247)
2.3 1.8-2.7 15.4 13.2-17.7 27 (10.9) 220 (89.1) 108 (43.7) 139 (56.3)
Mutation+/FISH +
(n = 163)
12.9 10.0-15.9 0.075 35.9 27.4-44.3 0.051 72 (44.2) 91 (55.8) 0.821 149 (91.4) 14 (9.6) 0.339
Mutation+/FISH-
(n = 89)
9.3 6.1-12.6 27.9 23.4-32.3 38 (42.7) 51 (57.3) 78 (87.6) 11 (12.4)
Mutation-/FISH +
(n = 62)
4.4 2.3-6.4 < 0.001 25.0 14.1-35.9 0.009 11 (17.7) 51 (82.3) 0.047 42 (67.7) 20 (32.3) < 0.001
Mutation-/FISH-
(n = 185)
2.0 1.7-2.3 14.2 11.5-16.9 16 (8.6) 169 (91.4) 66 (35.7) 119 (64.3)
Abbreviation: FISH, Fluorescent in situ hybridization; ORR, Objective response rate; DCR, Disease control rate; PFS, Progression-free survival; OS, Overall survival.
#p values (two-sided) calculated using the log-rank test.
*p values (two-sided) calculated using Pearson’s chi-square test.
Figure 1 Fluorescent in situ hybridization for epidermal growth factor receptor (EGFR) (orange signal) and centromere 7 (green signal)
showing low (disomy = A; high triomy = B) copy number per cell (EGFR-FISH negative), high (high polysomy = C; gene amplification = D)
copy number per cell (EGFR-FISH positive) (A-D, 1,000×).
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Table 2 Cox proportional regression analysis for progression-free survival and overall survival
Variable PFS OS
Univariate Multivariate Univariate
HR p HR p HR p
(95% CI) (95% CI) (95% CI)
Age 0.96 0.657 1.11 0.374
(<57 vs. γ 57) (0.79 to 1.16) (0.88 to 1.41)
Gender 0.63 < 0.001 0.87 0.310 0.54 < 0.001
(female vs. male) (0.52 to 0.77) (0.66 to 1.14) (0.42 to 0.69)
Smoking status 1.57 < 0.001 1.25 0.102 1.67 < 0.001
(never vs. ever) (1.29 to 1.92) (0.96 to 1.64) (1.31 to 2.12)
Histology 1.37 0.009 0.94 0.673 1.25 0.133
(ADC vs. non-ADC) (1.08 to 1.75) (0.72 to 1.24) (0.93 to 1.68)
Stage 1.00 0.976 0.87 0.190
(IIIb vs. IV) (0.83 to 1.20) (0.70 to 1.07)
ECOG 2.45 < 0.001 2.53 < 0.001 4.43 < 0.001
(0, 1 vs. 2, 3) (1.95 to 3.08) (1.97 to 3.24) (3.33 to 5.89)
LINE 1.32 0.006 1.06 0.618 1.40 0.006
(first-line vs.γ second-line) (1.09 to 1.61) (0.85 to 1.32) (1.10 to 1.78)
EGFR-TKI 1.14 0.201 1.14 0.312
(gefitinib vs. erlotinib) (0.93 to 1.40) (0.89 to 1.46)
EGFR mutation 0.37 < 0.001 0.42 <0.001 0.45 < 0.001
(wild-type vs. mutation) (0.31 to 0.45) (0.34 to 0.53) (0.36 to 0.58)
EGFR FISH 0.51 < 0.001 0.61 <0.001 0.51 < 0.001
(FISH- vs. FISH+) (0.42 to 0.62) (0.49 to 0.76) (0.40 to 0.65)
Abbreviation: ADC, Adenocarcinoma; ECOG, Eastern cooperative oncology group; TKI, Tyrosine kinase inhibitors; FISH, Fluorescent in situ hybridization.
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for PFS; HR, 0.70; 95% CI, 0.48 to 1.01; p = 0.057 for OS),
but the differences were not significant (Figure 2A, 2B).
And improved PFS in patients with mutation+/ampli-
fication (HR, 0.72; 95% CI, 0.50 to 1.03; p = 0.073)
was not significantly different compared to the patients
with mutation+/non-amplification. However, minor super-
ior OS was observed in patients with mutation+/amplifica-
tion (HR, 0.61; 95% CI, 0.38 to 0.98; p = 0.040).
Among the 247 patients with wild-type EGFR, 62
patients (25.1%) were EGFR-FISH + and were mostly
female (p = 0.030); there was no association with age,
smoking status, and histology (Table 3). Compared to the
mutation-/FISH- subgroup, the mutation-/FISH + patients
achieved a significantly higher ORR (17.7% vs. 8.6%,
p = 0.047), DCR (67.7% vs. 35.7%, p < 0.001), and longer
PFS (4.4 months vs. 2.0 months; HR, 0.56; 95% CI, 0.41 to
0.75; p < 0.001) and OS (25.0 months vs. 14.2 months; HR,
0.60; 95% CI, 0.41 to 0.89; p = 0.010) (Table 1, Figure 2C,
2D). Especially, favorable PFS was observed among
patients with EGFR amplification compared to low copy
number (5.0 months vs. 2.2 months; HR, 0.43; 95% CI,0.24 to 0.76; p = 0.003), but the trend did not affect OS
(16.6 months vs.15.4 months, HR, 0.65; 95% CI, 0.32 to
1.32; p = 0.228) (Figure 3A, 3B). On the other hand, in two
subgroups of EGFR-TKIs, superior PFS (5.6 months vs.
2.4 months; HR, 0.59; 95% CI, 0.40 to 0.87; p = 0.007
in gefitinib treatment subgroup, and 3.1 months vs.
1.5 months; HR, 0.68; 95% CI, 0.57 to 0.95; p = 0.005 in
erlotinib treatment subgroup) could be found in patients
with mutation-/FISH + compared to mutation-/FISH-.
Further analysis of the combined markers showed that
the 151 patients with either EGFR FISH + status or
EGFR mutations (single-positive) had an ORR of 32.5%,
a DCR of 79.5%, a median PFS of 7.9 months (95% CI,
5.4 to 10.4), and a median OS of 25.7 months (95% CI,
21.8 to 29.6). Thus, the clinical outcome of patients
with EGFR mutation+/FISH + was significantly better
than patients with a single-positive mutation and
FISH, or those with EGFR mutation-/FISH- (HR for group
mutation+/FISH + vs. mutation-/FISH-, 0.28; 95% CI, 0.22
to 0.35; p < 0.001; HR for group single-positive vs.
mutation-/FISH-, 0.41; 95% CI, 0.33 to 0.52; p < 0.001)
(Figure 2E, 2F).
Table 3 Association of EGFR FISH status and patient characteristics in the EGFR mutation stratum
Characteristics EGFR mutation EGFR wild-type
FISH + (n = 163) FISH - (n = 89) p FISH+ (n = 62) FISH - (n = 185) p
Age, years
Mean (range) 56.7 (29–83) 56.0 (28–80) 57.5 (38–86) 55.9 (23–80)
Gender 0.822 0.030
Male 83 (50.9) 44 (49.4) 35 (56.5) 132 (71.4)
Female 80 (49.1) 45 (50.6) 27 (43.5) 53 (28.6)
Smoking status 0.503 0.743
Non-smoker 120 (73.6) 62 (69.7) 36 (58.1) 103 (55.7)
Smoker 43 (26.4) 27 (30.3) 26 (41.9) 82 (44.3)
Histology 0.709 0.635
Adenocarcinoma 144 (88.3) 80 (89.9) 44 (71.0) 137 (74.1)
Non-adenocarcinoma 19 (11.7) 9 (10.1) 18 (29.0) 48 (25.9)
Prior platinum 0.426 0.582
Yes 106 (65.0) 57 (64.0) 42 (67.7) 135 (73.0)
No 53 (32.5) 27 (30.3) 18 (29.0) 42 (22.7)
Unknown 4 (2.5) 5 (5.6) 2 (3.2) 8 (4.3)
ECOG PS 0.453 0.454
0, 1 117 (71.8) 62 (69.7) 36 (58.1) 101 (54.6)
2, 3 35 (21.5) 17 (19.1) 14 (22.6) 56 (30.3)
Unknown 11 (6.7) 10 (11.2) 12 (19.4) 28 (15.1)
Disease stage 0.386 0.588
Recurrent 51 (31.3) 35 (39.3) 17 (27.4) 58 (31.4)
IIIb 27 (16.6) 15 (16.9) 15 (24.2) 34 (18.4)
IV 85 (52.1) 39 (43.8) 30 (48.4) 93 (50.3)
EGFR-TKI 0.996 0.845
Gefitinib 119 (73.0) 65 (73.0) 37 (59.7) 113 (61.1)
Erlotinib 44 (27.0) 24 (27.0) 25 (40.3) 72 (38.9)
Line of TKI therapy 0.515 0.344
Fist 39 (23.9) 22 (24.7) 11 (17.7) 32 (17.3)
Second 79 (48.5) 37 (41.6) 32 (51.6) 78 (42.2)
Higher 45 (27.6) 30 (33.7) 19 (30.6) 75 (40.5)
Abbreviation: FISH, Fluorescent in situ hybridization; ECOG, Eastern cooperative oncology group; PS, Performance status; TKI, Tyrosine kinase inhibitors.
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To date, there have been controversial reports on the
feasibility of using EGFR copy number to predict
whether NSCLC patients will benefit from TKI therapy.
In a prospective study [14], high EGFR copy number
was reported to be significantly associated with a better
response, and longer progression-free and overall sur-
vival in NSCLC patients treated with gefitinib. Then, the
trials (ISEL [19,29] and BR.21 [30]) indicated that EGFR
copy number may be a better predictive biomarker for
the efficacy of EGFR-TKI than EGFR mutation; but the
evidence seemed not much sufficient owing to being
placebo-controlled trials. Moreover, EGFR FISH + statusfailed to predict survival benefits from TKI treatment in
the INTEREST [20] and SATURN trials [31]. In the
IPASS trial [3], although PFS was significantly longer
with gefitinib treatment versus chemotherapy (HR, 0.66;
95% CI, 0.50 to 0.88) in patients with a high EGFR copy
number, the authors stated that predictive value was
attributed to the high overlap with a coexisting EGFR
mutation (77.6% of patients with high EGFR gene copy
number harbored a EGFR mutation). A similar conclu-
sion was also presented in the Takano’s report [32],
which demonstrated that high EGFR copy numbers are
caused by the selective amplification of mutant alleles,
according to the discovery of high copy numbers only in
Figure 2 Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) by combined analysis of epidermal growth
factor receptor (EGFR) mutation status and EGFR in fluorescent situ hybridization (FISH) status. (A) and (B), PFS and OS for FISH status in
the subgroup of patients with EGFR mutations; (C) and (D), PFS and OS for FISH status in the subgroup of patients with wild-type EGFR; (E) and
(F), PFS and OS for double-positive, double-negative, and single-positive EGFR mutations and FISH.
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tions. That may contribute to explain why in our study,
EGFR FISH + status provided no enhanced ability to pre-
dict TKI benefits compared to FISH-, although EGFR
FISH + status was an independent predictor of PFS (HR,
0.61; 95% CI, 0.49 to 0.76).
Regardless of EGFR-TKIs used in the first- and
second-line settings or maintenance treatment, the pres-
ence of mutated-EGFR indicated superior PFS or ORRcompared to comparator for therapy of NSCLC in
series of trials from the unselected population [20,33]
to the superior population [34], and the EGFR
mutation-positive population [4,5,7]. Consequently, the
overwhelming importance of EGFR mutation status has
been established for predicting efficacy and survival benefits
from EGFR-TKI.
While attention has been paid to patients with EGFR
mutations, closer care should be paid to patients with
Figure 3 Kaplan-Meier curves for PFS (A) and OS (B) by analysis of epidermal growth factor receptor (EGFR) amplification, high copy
number and low copy number in wild-type EGFR.
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when they should receive EGFR-TKI treatment. The
IPASS trial [3] found patients with a high EGFR gene
copy numbers had shorter PFS in the absence of an
EGFR mutation (HR, 3.85; 95% CI, 2.09 to 7.09). How-
ever, a recent study [35] reported that in patients with
wild-type EGFR who were diagnosed with squamous cell
carcinoma, high EGFR gene copy number correlated
well with response to EGFR-TKI therapy (27.3% vs. 4.2%,
respectively; p = 0.082) and PFS benefit (4.1 months vs.
2.1 months, p = 0.201), despite a marginally significant
difference due to the sample size. In this study, while
comparing the poor outcome of patients who were nega-
tive for both of mutations and FISH and had no clinical
benefit from EGFR-TKI treatment, we found that pa-
tients with FISH+/mutation- obtained favorable DCR
and survival benefit. Moreover, the elongated PFS was
more marked in the amplification/mutation- subgroup.
We presumed that EGFR FISH status displayed a
lower level of predictive sensitivity than mutation. Effect
of increased copy number was predominant once EGFR
gene was wild-type, no longer playing a full role of pre-
diction. Although evidence of the IPASS [34] and
TAILOR [36] trials indicated the superiority of using
chemotherapy in a first- and second-line to treat patients
who were EGFR mutation-negative, further study is
required to verify that EGFR FISH +may favor to choose
EGFR-TKIs or chemotherapy treatment in EGFR wild-
type population considering improved life-quality and
tolerable toxicity.
It is important to note that the variety of subsequent
treatments and the difficulty in obtaining detailed infor-
mation about these subsequent treatments are likely to
confound the true outcome of OS. A total of 63 patients
(12.5%), among whom 49 had a single-positive mutation
and FISH, continued receiving TKIs after diagnosis withadvanced disease until the physicians considered tumor
progression under control. In this study, we supposed
that directed by accumulated clinical experiences, a con-
tinued or second application of EGFR-TKIs may poten-
tially contribute to the survival gain in patients harboring
EGFR mutations or high copy number.
We are aware that some limitations might be of
concern in this study. This is a retrospective study, and
alterations in other kinases such as KRAS, BRAF, and
cMET that drive tumor growth were not investigated in
this study; thus it is possible that the survival and
response were affected, at least in part, by those under-
lying biomarkers. Further prospective, randomized trials
are warranted to confirm the efficacy of TKI in NSCLC
patients with wild-type EGFR combined with EGFR gene
copy number status.
In summary, this study demonstrated that EGFR gene
copy number can be further detected in patients with
wild-type EGFR, since patients in the FISH + subgroup
can derive a greater benefit from EGFR-TKI.Additional files
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